Clinical Trial Update: Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates aprepitant for management of pruritus caused by immune checkpoint inhibitors in patients with solid tumors; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus
• Solid Tumors

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Rabin Medical Center | Conditions: Pruritus | Phase 1 | Status: NOT_YET_RECRUITING